76 related articles for article (PubMed ID: 3309815)
21. Enoxacin decreases the clearance of theophylline in man.
Wijnands WJ; Vree TB; Van Herwaarden CL
Br J Clin Pharmacol; 1985 Dec; 20(6):583-8. PubMed ID: 3867394
[TBL] [Abstract][Full Text] [Related]
22. Enoxacin in the treatment of lower respiratory tract infections.
Philip-Joet F; Nourrit J; Frances Y; Arnaud A
J Antimicrob Chemother; 1988 Feb; 21 Suppl B():125-9. PubMed ID: 3258863
[TBL] [Abstract][Full Text] [Related]
23. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients.
Deneke J; Luckow V; Guserle R; Pässler HH
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):418-24. PubMed ID: 9726694
[TBL] [Abstract][Full Text] [Related]
24. [C-reactive protein concentrations during initial (empiric) treatment of neonatal sepsis].
Janković B; Pasić S; Marković M; Veljković D; Milicić M
Srp Arh Celok Lek; 2001; 129 Suppl 1():17-22. PubMed ID: 15637985
[TBL] [Abstract][Full Text] [Related]
25. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
Bailey RR; Walker RJ; Lynn KL; Donaldson IM; Peddie BA; Dobbs BR
Br J Clin Pharmacol; 1988 Feb; 25(2):223-8. PubMed ID: 3162809
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days.
Tsuei SE; Darragh AS; Brick I
J Antimicrob Chemother; 1984 Sep; 14 Suppl C():71-4. PubMed ID: 6389477
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetics of enoxacin in elderly patients.
Wise R; Baker SL; Misra M; Griggs D
J Antimicrob Chemother; 1987 Mar; 19(3):343-50. PubMed ID: 3471751
[TBL] [Abstract][Full Text] [Related]
28. [Long-term treatment and clinical evaluation of enoxacin in complicated urinary tract infections].
Washida H; Sakagami H; Iwase Y; Sasaki S
Hinyokika Kiyo; 1987 Sep; 33(9):1508-12. PubMed ID: 3481218
[TBL] [Abstract][Full Text] [Related]
29. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
Arens PJ
Med Klin Prax; 1982 Aug; 77(18):48-53, 67. PubMed ID: 6752679
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
31. The effect of age on the pharmacokinetics of enoxacin.
Dobbs BR; Gazeley LR; Campbell AJ; Edwards IR
Eur J Clin Pharmacol; 1987; 33(1):101-4. PubMed ID: 3480221
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
Wilms EB; Touw DJ; Heijerman HG
Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
[TBL] [Abstract][Full Text] [Related]
33. Elimination of enoxacin in renal disease.
Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
[TBL] [Abstract][Full Text] [Related]
34. [Penetration of cefotaxime into bronchial secretions].
Bergogne-Berezin E; Morel C; Pierre J; Monrocq N; Dournovo P; Benard Y
Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):501-5. PubMed ID: 6289226
[TBL] [Abstract][Full Text] [Related]
35. [Expression and significance of beta(2)-adrenoreceptor in inflammatory cells of patients with chronic obstructive pulmonary disease].
Zhu WJ; He B; Xu M
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2099-102. PubMed ID: 19080468
[TBL] [Abstract][Full Text] [Related]
36. [The effect of salmeterol on the number of hypodense eosinophils, eosinophilic cationic protein levels ECP in serum, bronchial hyperresponsiveness and lung function test in patients with bronchial asthma].
Chazan R; Grubek-Jaworska H; Hermanowicz-Salomon J; Droszcz W
Pol Merkur Lekarski; 1997 Oct; 3(16):180-2. PubMed ID: 9461726
[TBL] [Abstract][Full Text] [Related]
37. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
Wolf R; Eberl R; Dunky A; Mertz N; Chang T; Goulet JR; Latts J
J Antimicrob Chemother; 1984 Sep; 14 Suppl C():63-9. PubMed ID: 6389476
[TBL] [Abstract][Full Text] [Related]
38. [Epidemiologic and therapeutic studies on gonorrheal infections--use of AT-2266--Sapporo Clinical Research Group for STD].
Kumamoto Y; Sakai S; Tamate H; Gohro T; Inoke T; Tabata S; Tanda H; Kato S; Saka T; Henmi I
Hinyokika Kiyo; 1986 Aug; 32(8):1185-202. PubMed ID: 3466520
[TBL] [Abstract][Full Text] [Related]
39. [Effect of 16-week use of salmeterol on ECP levels, pulmonary function tests and bronchial hyperreactivity in patients with chronic obstructive lung disease].
Chazan R; Jaworski A; Grubek-Jaworska H; Droszcz W
Pol Tyg Lek; 1995 Oct; 50(40-44):48-9, 63. PubMed ID: 8650060
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
